RxDoctor Payments DataLook up a doctor →

Kenneth Grossman, MD

Procedural Dermatology · Little Silver, NJNPI 1427012533

Payments from drug & device makers

$9,121in general payments, 2019–2025

Across 530 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$2K
  • LEO Pharma Inc.$553
  • Regeneron Healthcare Solutions, Inc.$454
  • Lilly USA, LLC$436
  • Novartis$418
  • plus $4K from 28 others

What the payments were for

  • Food & beverage$8,50693%
  • Education$6167%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,121 in reported general payments places this provider in the 90th percentile of 22 procedural dermatology providers in New Jersey.

See all procedural dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$404,325
Medicare patients
1,267
Services billed
7,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast19$93,357
Dupixent SyringeDupilumab18$81,154
Humira(Cf) PenAdalimumab11$71,628
Dupixent PenDupilumab13$43,726
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc131$8,227
Metronidazole116$6,219
Halobetasol Propionate150$5,625
Clobetasol Propionate106$5,052
Triamcinolone Acetonide34$3,045
Mupirocin399$2,533
Ketoconazole131$2,278
Mometasone Furoate123$2,236
Fluticasone Propionate132$1,829
Doxycycline Hyclate56$1,822
Desonide54$1,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$365$93,35719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 22 procedural dermatology providers in New Jersey.

Other procedural dermatology in Little Silver

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →